This observation aligns with preclinical results in which the nanoparticle formulation of AZD2811 displayed slower onset and more prolonged inhibition of AURKB in tumours compared with barasertib, together with more effective tumour growth inhibition in multiple models [23]. The gene discussed is AURKB; the disease is neoplasm.